Annual Report 2008 of Beximco Pharmaceuticals Limited

It is a broadly described annual report of Beximco Pharmaceuticals Limited in the year of 2008. During the year under review, overall sales of the company registered an appreciable 11.50% growth to reach Tk. 4,010.16 million as compared to 3,597.02 million in 2007. In 2008 the company achieved a pre-tax profit of Tk. 714.12 million registering 78.67% growth over Tk. 399.68 million in 2007. In 2008, The Company has achieved export sales of Tk. 170.60 million- a significant 39% growth over Tk. 122.75 million in 2007. The earning per share (EPS) of the company also improved to Tk. 4.33 from Tk.2.80 in comparable terms.

The Board of Directors has recommended 10% cash and 20% stock dividend for approval of the shareholders for the year ended 31st December 2008. These financial statements are presented in Bangladesh Taka (Taka/Tk/BDT) which is the company’s functional currency. All financial information presented in Taka has been rounded off to the nearest Taka.

More Annual Report of Beximco Pharmaceuticals Limited :

  1. Annual Report 2001 of Beximco Pharmaceuticals Limited
  2. Annual Report 2002 of Beximco Pharmaceuticals Limited
  3. Annual Report 2003 of Beximco Pharmaceuticals Limited
  4. Annual Report 2004 of Beximco Pharmaceuticals Limited
  5. Annual Report 2005 of Beximco Pharmaceuticals Limited
  6. Annual Report 2006 of Beximco Pharmaceuticals Limited
  7. Annual Report 2007 of Beximco Pharmaceuticals Limited
  8. Annual Report 2008 of Beximco Pharmaceuticals Limited
  9. Annual Report 2009 of Beximco Pharmaceuticals Limited
  10. Annual Report 2010 of Beximco Pharmaceuticals Limited
  11. Annual Report 2011 of Beximco Pharmaceuticals Limited
  12. Annual Report 2012 of Beximco Pharmaceuticals Limited
  13. Annual Report 2013 of Beximco Pharmaceuticals Limited
  14. Annual Report 2014 of Beximco Pharmaceuticals Limited
  15. Auditors’ Report 2015 of Beximco Pharmaceuticals Limited
  16. Annual Report 2016 of Beximco Pharmaceuticals Limited
  17. Auditors’ Report 2017 of Beximco Pharmaceuticals Limited